Close this search box.
WVU neuroscientists are studying whether wearing glasses with orange lenses at night can improve outcomes in cardiac patients. The glasses filter out blue light, which the researchers tied to inflammation, brain-cell death and greater mortality in a recent study based on animal models.

WVU researchers identify how light at night may harm outcomes in cardiac patients

In a study funded by the National Institutes of Health, West Virginia University neuroscientists linked white light at night—the kind that typically illuminates hospital rooms—to inflammation, brain-cell death and higher mortality risk in cardiac patients. 

Randy Nelson, who chairs the Department of Neuroscience in the WVU School of Medicine, and Courtney DeVries, the John T. and June R. Chambers Chair of Oncology Research at WVU, re-created cardiac arrest in animal models. Doing so temporarily interrupted the brain’s oxygen supply. Then the researchers and their colleagues divided the models into three groups that would spend their nights in—respectively—dim red light, dim white light and the dark. 

After seven nights of this regimen, the researchers evaluated the health of the models’ brain cells. Exposure to white light at night caused multiple poor outcomes. The researchers’ findings are published in Experimental Neurology. 

Cardiac arrest was more likely to be lethal for models in the white-light-at-night group, whereas the mortality rate in the red-light-at-night group did not differ from the group that stayed in darkness. 

Exposure to white light at night also correlated to greater cell death in the hippocampus—a part of the brain that’s key to memory formation—and more aggressive inflammation overall. In fact, just one dimly illuminated night was enough to cause pro-inflammatory cytokines—tiny proteins critical to immune responses—to surge. This was only the case, however, if the light was white. Red light had no effect. 

“When you see long-wavelength, blue light first thing in the morning, those long wavelengths set your circadian clock to precisely 24 hours. The problem is, if you see blue light at night—from your phones, TVs, computers and compact fluorescent lights—they’re disrupting your circadian system all night long. Those lights look white to us, but frankly, they’re mostly blue,” explained Nelson, who—along with DeVries—receives support from the West Virginia Clinical and Translational Science Institute. His previous research has associated nocturnal blue light with higher rates of obesity, metabolic disorders and depression.

“Clearly light at night is required in patients’ rooms acutely after cardiac arrest and other major health events,” said Laura Fonken, lead author on the study and an assistant professor at the University of Texas at Austin. “Our data suggest that a relatively simple shift—changing the light color from broad-spectrum white to a red hue—benefits outcomes in an animal model of cardiac arrest. If this also occurs in clinical populations, then it would be important because it would not require complicated clinical trials to implement for patients and could improve recovery from various other health events that require hospital stays.”

To that end, the researchers are exploring whether white light at night provokes a similar physiological response in people. For four nights in a row, they outfit one group of hospitalized cardiac patients in special “gaming glasses” with orange lenses that filter out the troublesome blue light. Wearing the glasses seems to bathe everything in warm, sunset tones. Another group of patients wears identically shaped glasses that have clear lenses, allowing the full spectrum of white light—including blue tones—to pass through.

“The cool thing from our perspective is, we believe these longer-wavelength lights won’t have that detrimental effect, and people will recover faster,” Nelson said. If studies bear out the researchers’ hunch, gaming glasses may be an affordable, practical option for preserving brain function, reducing inflammation and lowering the risk of death in cardiac patients. 

Research reported in this publication was supported by the US-Israeli Binational Research Foundation, the National Institutes of Health under Award Number 1R01NS092388 and the West Virginia Clinical and Translational Science Institute. WVCTSI is funded by an IDeA Clinical and Translational grant from the National Institute of General Medical Sciences, under Award Number U54GM104942, to support the mission of building clinical and translational research infrastructure and capacity to impact health disparities in West Virginia.

News Feed

Subscribe to remove popups, or just enjoy this free story and support our local businesses!